Kyushu University Academic Staff Educational and Research Activities Database
Researcher information (To researchers) Need Help? How to update
Hideya Onishi Last modified date:2019.05.29

Associate Professor / Department of Cancer Therapy and Research
Department of Advanced Medical Initiatives
Faculty of Medical Sciences

Graduate School
Undergraduate School

The guidance of cancer-immuno therapy in Cancer Therapy and research in Kyushu University faculty of Medicine .
Academic Degree
Doctor of Medicine
Field of Specialization
tumor immunity
Outline Activities
Research; development of immunotherapy using dendritic cells and development of therapeutic strategy targeting Hedgehog signaling.
I tell students to have research mind and understand translational research.
Research Interests
  • Developing of therapy of regulatiing pancreatic fibrosis using Ptch1 peptide for improving immunotolerance of patients with pancreatic cancer
    keyword : patients with oancreatic cancer, improving immunotolerance, Ptch1 peptide, inhibition of pancreatic fibrosis
  • Analysis of TrkB/BDNF signaling for developing new therapeutic strategy against pancreatic cancer
    keyword : pancreatic cancer, TrkB/BDNF signal, new therapeutic strategy
  • developing of therapy against thymic cancer targeting TrkB/BDNF signaling
    keyword : thymic cancer, TrkB/BDNF signaling, developing cancer therapy
  • Analysis of Smo transcriptional pathway for developing new Hedgehog signaling-regulating therapy
    keyword : Hedgehog signal, Smo, transcription, cancer therapy
  • Development of VEGFR2-targetting therapy for controling regulatory T cells.
    Possible cancer immunotherapy in hypoxia environment.
    Contribution of hedgehog signal for the increase of the invasive activity in pancreatic cancer under hypoxia condition.
    keyword : VEGFR2, regulatory T cells
Academic Activities
1. Hideya Onishi, 森崎 隆, Mitsuo Katano, Regulatory T cell: Immunotherapy of Cancer: An Innovative Treatment Comes of Age. , Springer Japan, Tokyo, 2015.05.
1. Hideya Onishi, Mitsuo Katano, Hedgehog signaling pathway as a new therapeutic target in pancreatic cancer., World J Gastroenterol, 2014.03.
2. Morisaki T, Onishi H, Katano M. , Cancer immunotherapy using NKG2D and DNAM-1 systems. , Anticancer Res, 2012.06.
3. Onishi H, Katano M, Immunotherapy approaches targeting regulatory T-cells, Anticancer Res, 2012.03.
4. Onishi H and Katano M, Hedgehog signaling pathway as a therapeutic target in various types of cancer., Cancer Science, 2011.10.
5. Onishi H, Morisaki T, Baba E, Nakamura M, Inaba S, Kuroki H, Matsumoto K, Katano M, Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma., Anticancer Res, 2011.11.
6. Onishi H, Morisaki T, Kuga H, Katano M, Doi F, Uchiyama A, Sugitani A, Wada J, Chijiiwa K, Tanaka M. , A large quantity of CD3-/CD19-/CD16- lymphocytes in malignant pleural effusion from a patient with recurrent cholangio cell carcinoma.

, Immunol Invest. 2002 May;31(2):121-35., 2006.06.
1. Hideya Onishi, Akiko Fujimura, Yasuhiro Oyama, Akio Yamasaki, Akira Imaizumi, Makoto Kawamoto, Mitsuo Katano, Masayo Umebayashi, Takashi Morisaki, Hedgehog signaling regulates PDL-1 expression in cancer cells to induce anti-tumor activity by activated lymphocytes. , Cell Immunol, 2017.05.
2. Makoto Kawamoto, Hideya Onishi, Keigo Ozono, Akio Yamasaki, Akira Imaizumi, Sachiko Kamakura, Kenji Nakano, Yoshinao Oda, Hideki Sumimoto, Masafumi Nakamura, Tropomyosin-related kinase B mediated signaling contributes to the induction of malignant phenotype of gallbladder cancer., Oncotarget, 2017.05, Purpose: BDNF/TrkB signaling has been shown to be associated with aggressive phenotype in some cancers, but has not yet been investigated in gallbladder cancer (GBC). This study aims to analyze the biological significance of BDNF/TrkB signaling in GBC, and explore its potential as a novel therapeutic target.
Experimental Design: We investigated TrkB expression clinically in 69 resected primary GBC specimens, and examined the correlation between TrkB expression and clinicopathological findings by immunohistochemistry. We used five TrkB-expressing GBC cell lines with or without K-ras mutation for in vitro investigations, and analyzed tumorigenesis and tumor growth of TrkB siRNA-transfected GBC cells in vivo using a xenograft model.
Results: TrkB expression was detected in 63 (91.3%) clinical GBC specimens. TrkB expression in the invasive front correlated with T factor (p=0.0391) and clinical staging (p=0.0391). Overall survival was lower in patients with high TrkB expression in the invasive front than in those with low TrkB expression (p=0.0363). In vitro, proliferation was unaffected by rhBDNF treatment; however, K252a treatment and TrkB siRNA transfection decreased proliferation. rhBDNF treatment increased invasiveness by inducing EMT and activating MMP-2/MMP-9, whereas K252a treatment abrogated these effects. TrkB or BDNF siRNA transfection suppressed invasiveness. TrkB siRNA transfection decreased HIF-1α, VEGF-A, and VEGF-C/-D expression. In vivo, TrkB siRNA transfection decreased tumorigenicity and tumor growth in GBC.
Conclusions: These findings demonstrate that TrkB-mediated signaling is associated with malignant phenotypes (proliferation, invasiveness, angiogenesis, lymphangiogenesis, and tumorigenesis) in GBC, and could be a novel therapeutic target regardless of K-ras mutation status..
3. Suyama K, Hideya Onishi, Imaizumi A, Shinkai K, Umebayashi M, Makoto Kubo, Mizuuchi Y, Yoshinao Oda, Masao Tanaka, Masafumi Nakamura, Mitsuo Katano, CD24 suppresses malignant phenotype by downregulation of SHH transcription through STAT1 inhibition in breast cancer cells. , Cancer Lett, 374, 1, 44-53, 2016.01.
4. Hideya Onishi, Yamasaki A, Kawamoto M, Imaizumi A, Mitsuo Katano, Hypoxia but not normoxia promotes Smoothened transcription through upregulation of RBPJ and Mastermind-like 3 in pancreatic cancer., Cancer Lett, 371, 2, 143-150, 2016.02.
5. Shojiro Matsushita, Hideya Onishi, Kenji Nakano, Iori Nagamatsu, Akira Imaizumi, Masami Hattori, Yoshinao Oda, Masao Tanaka, Mitsuo Katano, Hedgehog signaling pathway is a potential therapeutic target for gallbladder cancer., Cancer Sci, 105, 3, 272-280, 2014.03.
6. Seiichi Odate, Hideya Onishi, Katsuya Nakamura, Masayuki Kojima, Akihiko Uchiyama, Masato Kato, Mitsuo Katano, Tropomyosine related kinase B inhibitor has potential for tumor regression and relapse prevention in pulmonary large cell neuroendocrine carcinoma. , Anticancer Res, 2013.09.
7. Hideya Onishi, Takashi Morisaki, A Kiyota, N Koya, H Tanaka, M Umebayashi, Mitsuo Katano, The Hedgehog inhibitor suppresses the function of monocyte-derived dendritic cells from patients with advanced cancer under hypoxia., Biochem Biophys Res Commun., 2013.08.
8. Takashi Morisaki, M Umebayashi, A Kiyota, N Koya, H Tanaka, Hideya Onishi, Mitsuo Katano, Combining celecoxib with sorafenib synergistically inhibits hepatocellular cells in vitro., Anticancer Res, 33, 4, 1387-1395, 2013.04.
9. Hideya Onishi, Takashi Morisaki, A Kiyota, N Koya, H Tanaka, M Umebayashi, Mitsuo Katano, The Hedgehog inhibitor cyclopamine impairs the benefits of immunotherapy with activated T and NK lymphocytes derived from patients with advanced cancer. , Cancer Immunol Immunother, 2013.08.
10. Hideya Onishi, Takafumi Morisaki, F Nakao, Seiichi Odate, Takashi Morisaki, Mitsuo Katano, Protein-bound polysaccharide decreases invasiveness and proliferation in pancreatic cancer by inhibition of hedgehog signaling and HIF-1 pathways under hypoxia. , Cancer Lett, 2013.07.
11. Seiichi Odate, Katsuya Nakamura, Hideya Onishi, Masayuki Kojima, Y Uchiyama, Kenji Nakano, Masato Kato, TrkB/BDNF signaling pathway is a potential therapeutic target for pulmonary large cell meuroendocrine carcinoma. , Lung Cancer, 79, 3, 205-214, 2013.03.
12. Hironori Iwasaki, Kenji Nakano, Kentaro Shinkai, Y Kunisawa, M Hirahashi, Yoshinao Oda, Hideya Onishi, Mitsuo Katano, Hedgehog Gli3 activator signal augments tumorigenicity of colorectal cancer via up-regulation of adherence-related genes., Cancer Sci, 104, 3, 328-336, 2013.03.
13. Hiroyuki Suzuki, Hideya Onishi, Takashi Morisaki, Masao Tanaka, Mitsuo Katano, Intratumoral FOXP3+VEGFR2+ Regulatory T Cells Are Predictive Markers for Recurrence and Survival in Patients with Colorectal Cancer., Clin Immunol, 26-33, 2013.01.
14. Masato Kato, Hideya Onishi, Kotaro Matsumoto, Nobuko Tsuruta, Kazuyuki Higuchi, Juniichi Motoshita, Mitsuo Katano, Preoperative Chemoradiotherapy Using Cisplatin plus S-1
Can Induce Downstaging in Patients with Locally Advanced (Stage III) Non-Small-Cell Lung Cancer.
, Anticancer Res, 5099-5104, 2012.11.
15. Kubo M*, Onishi H*, Kuroki S, Okido M, Shimada K, Yokohata K, Umeda S, Ogawa T, Tanaka M, Katano M. (Co-contributor), Short-term and low-dose prednisolone administration reduces aromatase inhibitor-induced arthralgia in patients with breast cancer., Anticancer Res, 32, 6, 2331-2336, 2012.06.
16. Onishi H, Koya N, Kiyota A, Tanaka H, Umebayashi M, Katano M, Morisaki T., A new method for rapid cytotoxic T-lymphocyte induction using a multiple cytokine cocktail., Anticancer Res, 32, 6, 2385-2390, 2012.06.
17. Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M., Combining cetuximab with killer lymphocytes synergistically inhibits human cholangiocarcinoma cells in vitro. , Anticancer Res, 32, 6, 2249-2256, 2012.06.
18. Hideya Onishi, Yoshihiro Morifuji, Masaya Kai, Kumi Suyama, Hironori Iwasaki, Mitsuo Katano, Hedgehog inhibitor decreases chemosensitivity to 5-fluorouracil and gemcitabine under hypoxic condition in pancreatic cancer, Cancer Sci, 2012.10.
19. Ogino T, Onishi H, Suzuki H, Morisaki T, Tanaka M, Katano M, Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions., Cancer Immunol Immunother, 61, 3, 409-424, 2012.03.
20. Kai M, Onishi H, Souzaki M, Tanaka H, Kubo M, Tanaka M, Katano M. , Semi-quantitative evaluation of CD44(+) /CD24(-) tumor cell distribution in breast cancer tissue by a newly developed fluorescence immunohistochemical staining method., Cancer Sci, 102, 12, 2132-2138, 2011.12.
21. Xu R, Nakano K, Iwasaki H, Kumagai M, Wakabayashi R, Yamasaki A, Suzuki H, Mibu R, Onishi H, Katano M, Dual blockade of phosphatidylinositol 3'-kinase and mitogen-activated protein kinase pathways overcomes paclitaxel-resistance in colorectal cancer., Cancer Lett, 306, 2, 151-160, 2011.07.
22. Souzaki M, Kubo M, Kai M, Kameda C, Tanaka H, Taguchi T, Tanaka M, Onishi H, Katano M, Hedgehog signaling pathway mediates the progression of non-invasive breast cancer to invasive breast cancer., Cancer Sci, 102, 373-381, 2011.02.
23. Tasaka T, Akiyoshi T, Yamaguchi K, Tanaka M, Onishi H, Katano M:, Gamma-secretase complexes regulate the responses of human pancreatic ductal adenocarcinoma cells to taxanes., Anticance Res, 30, 4999-5010, 2010.12.
24. Wada J*, Onishi H*, Suzuki H, Yamasaki A, Nagai S, Morisaki T, Katano M (* co-contributor), Surface-bound TGF-beta1 on effusion-derived exosomes participates in the maintenance of both number and suppressive function of regulatory T cells in malignant effusions., Anticancer Res, 30, 9, 3747-3757, 2010.09.
25. Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, Katano M. , Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells., Anticancer Res, 30, 6, 2041-2048, 2010.06.
26. Onishi H, Kai M, Odate S, Iwasaki H, Morifuji Y, Ogino T, Morisaki T, Nakashima Y, Katano M:, Hypoxia activates the hedgehog signaling pathway in a ligand-independent manner by upregulation of Smo transcription in pancreatic cancer. , Cancer Sci., 2011.06.
27. Kameda C, Nakamura M, Tanaka H, Yamasaki A, Kubo M, Tanaka M, Onishi H, and Katano M, Estrogen receptor α (ER α) contributes to the regulation of hedgehog signaling pathway in ER α positive gastric cancer., Brt J Cancer, 102, 738-747, 2010.02.
28. Suzuki H*, Onishi H*, Wada J, Yamasaki A, Tanaka H, Nakano K, Morisaki T, Katano M (* co-contributor), VEGFR2 is selectively expressed by FOXP3highCD4+ Treg., Eur. J, Immunol., 40, 197-203, 2010.01.
29. Onishi H, Kuroki H, Matsumoto K, Baba E, Kuga H, Tanaka M, Katano M, Morisaki T, Dysfunctional and short-lived subsets in monocyte-derived dendritic cells from patients with advanced cancer., Clinical Immunology 105:286-295, 2002, 10.1006/clim.2002.5293, 105, 3, 286-295, 2002.12.
30. Onishi H, Kuroki H, Matsumoto K, Baba E, Sasaki N, Kuga H, Tanaka M, Katano M, Morisaki T, Monocyte-derived dendritic cells that capture dead tumor cells secrete IL-12 and TNF-? through IL-12/TNF-?/NF-?B autocrine loop., Cancer Immunol Immunother 53:1093-1100, 2004, 10.1007/s00262-004-0568-y, 53, 12, 1093-1100, 2004.12.
31. Onishi H, Morisaki T, Kuroki H, Matsumoto K, Baba E, Kuga H, Tanaka M, and Katano M:, Evaluation of a dysfunctional and short-lived subset of monocyte-derived dendritic cells from cancer patients., Anticancer Res 25(5):3445-51, 2005, 25, 5, 3445-3451, 2005.09.
32. Kuga H, Morisaki T, Nakamura K, Onishi H, Uchiyama A, Noshiro H, Tanaka M, Katano M:, Interferon-? suppresses transforming growth factor-?? -induced invasion of gastric carcinoma cells through cross-talk of Smad pathway in a three-dimensional culture model., Oncogene 22:7838-7847,2003, 10.1038/sj.onc.1207046, 22, 49, 7838-7847, 2003.10.